{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:56:44Z","timestamp":1775084204156,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002706","name":"AFA F\u00f6rs\u00e4kring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska Universitetssjukhuset","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Selective serotonin reuptake inhibitors (<jats:styled-content style=\"fixed-case\">SSRI<\/jats:styled-content>s) may aggravate anxiety and agitation during the first days of treatment but the frequency of such reactions remains unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We analysed patient\u2010level data from placebo\u2010controlled trials of sertraline, paroxetine or citalopram in depressed adults. Somatic anxiety, psychic anxiety and psychomotor agitation as assessed using the Hamilton Depression Rating Scale (HDRS) were analysed in all trials (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>8262); anxiety\u2010related adverse events were analysed in trials investigating paroxetine and citalopram (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>5712).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After one but not two weeks, patients on an SSRI were more likely than those on placebo to report enhanced somatic anxiety (adjusted risk 9.3% vs. 6.7%); likewise, mean rating of somatic anxiety was higher in the SSRI group. In contrast, patients receiving an SSRI were less likely to report aggravation of psychic anxiety (adjusted risk: 7.0% vs. 8.5%) with mean rating of psychic anxiety and agitation being lower in the SSRI group. The adverse event \u2018nervousness\u2019 was more common in patients given an SSRI (5.5% vs. 2.5%). Neither aggravation of HDRS\u2010rated anxiety nor anxiety\u2010related adverse events predicted poor antidepressant response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Whereas an anxiety\u2010reducing effect of <jats:styled-content style=\"fixed-case\">SSRI<\/jats:styled-content>s is notable already during the first week of treatment, these drugs may also elicit an early increase in anxiety in susceptible subjects that however does not predict a poor subsequent response to treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/acps.12784","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T17:16:40Z","timestamp":1504199800000},"page":"343-351","source":"Crossref","is-referenced-by-count":22,"title":["Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression"],"prefix":"10.1111","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2782-5160","authenticated-orcid":false,"given":"J.","family":"N\u00e4slund","sequence":"first","affiliation":[{"name":"Department of Pharmacology Sahlgrenska Academy University of Gothenburg Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0930-6068","authenticated-orcid":false,"given":"F.","family":"Hieronymus","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Sahlgrenska Academy University of Gothenburg Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Emilsson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Sahlgrenska Academy University of Gothenburg Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lisinski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Sahlgrenska Academy University of Gothenburg Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4748-0446","authenticated-orcid":false,"given":"S.","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Institute of Mathematical Sciences Chalmers University of Technology Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-2046","authenticated-orcid":false,"given":"E.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Sahlgrenska Academy University of Gothenburg Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048371"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198902000-00006"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb07749.x"},{"key":"e_1_2_9_5_1","unstructured":"U.S. Food and Drug Administration.CfDEaR Guidance for Industry Celexa NDA 20\u2010822 approval letter statistical review (part 2) 1998."},{"key":"e_1_2_9_6_1","unstructured":"U.S. Food and Drug Administration.CfDEaR Guidance for Industry Paxil CR NDA 20\u2010982 & 20\u2010936\/S008 approval letter statistical review 2002."},{"key":"e_1_2_9_7_1","unstructured":"U.S. Food and Drug Administration.CfDEaR Guidance for Industry Paxil NDA 020031 approval letter statistical review 1992."},{"key":"e_1_2_9_8_1","unstructured":"U.S. Food and Drug Administration.CfDEaR Guidance for Industry Zoloft NDA 019839 approval letter statistical review 1991."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.53"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.104"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150103500425"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2010.11.003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20917"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32835bc703"},{"key":"e_1_2_9_15_1","first-page":"1245","article-title":"Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta\u2010analysis","volume":"159","author":"Trindade E","year":"1998","journal-title":"CMAJ"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199703\/04)12:2<127::AID-HUP848>3.0.CO;2-Y"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.3.387"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957040-00005"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.132"},{"key":"e_1_2_9_20_1","first-page":"100","article-title":"The jitteriness syndrome in panic disorder patients treated with antidepressants","volume":"49","author":"Pohl R","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119300700305"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1002"},{"key":"e_1_2_9_23_1","first-page":"435","article-title":"Use of low\u2010dose fluoxetine in major depression and panic disorder","volume":"54","author":"Louie AK","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20438"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00216062"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90210-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290073009"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.85"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2011.48"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facps.12784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.12784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:44:07Z","timestamp":1695473047000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.12784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/acps.12784"],"URL":"https:\/\/doi.org\/10.1111\/acps.12784","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}